Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization
The purpose of this study was to investigate whether ultra-high-field dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the breast at 7T using quantitative pharmacokinetic (PK) analysis can differentiate between benign and malignant breast tumors for improved breast cancer diagnosis...
Main Authors: | R. Elena Ochoa-Albiztegui, Varadan Sevilimedu, Joao V. Horvat, Sunitha B. Thakur, Thomas H. Helbich, Siegfried Trattnig, Elizabeth A. Morris, Jeffrey S. Reiner, Katja Pinker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3763 |
Similar Items
-
Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results
by: Doris Leithner, et al.
Published: (2019-09-01) -
Fat Composition Measured by Proton Spectroscopy: A Breast Cancer Tumor Marker?
by: Almir Bitencourt, et al.
Published: (2021-03-01) -
Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
by: Zhuo Ye, et al.
Published: (2015-08-01) -
The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up
by: Lombardi A, et al.
Published: (2021-04-01) -
Matrix Metalloproteinase-2 Expression as a Prognostic Marker in Breast Carcinomas
by: B Jayashre, et al.
Published: (2021-04-01)